The administration of IV iron to treat anemia during acute infection remains controversial owing to concerns of exacerbating the infection. We conducted a retrospective cohort study using the TriNetX Research Network (2000 to June 2025) to evaluate the safety and efficacy of IV iron administration in adults with iron deficiency anemia and infection (methicillin-resistant Staphylococcus aureus [MRSA] bacteremia, pneumonia, urinary tract infection [UTI], colitis, or cellulitis). Patients must have received antibiotic agents within 2 days of infection for inclusion and were stratified by IV iron exposure. Propensity matching (1:1) was performed within each cohort. Survival was significantly higher (P< .001 for each infection type) at both 14 and 90 days in patients who received IV iron (MRSA bacteremia, 97.6% vs 95.0% and 88.6% vs 83.8%; pneumonia, 95.7% vs 91.5% and 84.7% vs 78.1%; UTI, 97.6% vs 95.7% and 89.1% vs 85.6%; colitis, 97.6% vs 95.5% and 89.7% vs 83.8%; and cellulitis, 98.5% vs 97.4% and 92.2% vs 89.2%). Hemoglobin recovery 60 to 90 days after infection was significantly greater (all P< .001) when IV iron was administered across all subgroups (MRSA bacteremia, +1.3 vs +1.0 g/dL; pneumonia, +1.3 vs +1.0 g/dL; UTI, +1.4 vs +1.0 g/dL; colitis, +1.5 vs +0.7 g/dL; and cellulitis, +1.4 vs +0.9 g/dL). The findings observed for each infection type studied suggest that IV iron administration during acute infection does not exacerbate infection and is associated with improved survival and enhanced recovery from anemia in hospitalized patients. Prospective studies are needed to confirm these findings and expand their applicability.
This is a remarkable proof-of-concept study—11 out of 11 patients with multi-refractory AIHA achieved complete remission after CD19 CART, with rapid Hb normalization and a median drug-free remission of 11.5 months. Toxicity was surprisingly manageable (mostly grade 1–2 cytokine release syndrome (CRS)), and the relapse biology pointing to BCMA+ long-lived plasma cells really sets up a rational next step with plasma cell–directed strategies.
Rare disease process that can carry significant morbidity. It is encouraging to see 40% response in such patient population when no other therapies (this is a first-in class) exist besides supportive care with very favorable toxicity profile.
A single-group, phase 1–2 study indicated that eltrombopag improved the efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin (ATG) plus cyclosporine in patients with severe aplastic anemia.